Przegląd Dermatologiczny

Full text

1/2026 vol. 113
Original article

Expression of Inflammatory Markers in Epidermis of Diabetic Patients – Preliminary Results

Wojciech Matuszewski 1
,
Bernard Kordas 1
,
Robert Modzelewski 1
,
Judyta Juranek 1

  1. Department of Human Physiology and Pathophysiology, School of Medicine, University of Warmia and Mazury, Olsztyn, Poland


Dermatol Rev/Przegl Dermatol 2026, 113, 1–7

DOI: https://doi.org/10.5114/dr.2026.162083
Data publikacji online: 2026/06/05
Article file
Expression of inflammatory.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Mauricio D., Alonso N., Gratacòs M.: Chronic diabetes complications: the need to move beyond classical concepts. Trends Endocrinol Metab 2020, 31, 287-295.
  2. Galiero R., Caturano A., Vetrano E., Beccia E., Brin C., Alfano M., et al.: Peripheral neuropathy in diabetes mellitus: pathogenetic mechanisms and diagnostic options. Int J Mol Sci 2023, 24, 3554.
  3. Swoboda L., Held J.: Impaired wound healing in diabetes. J Wound Care 2022, 31, 882-885.
  4. David P., Singh S., Ankar R.: A comprehensive overview of skin complications in diabetes and their prevention. Cureus 2023, 15, e38961.
  5. de Macedo G.M.C., Nunes S., Barreto T.: Skin disorders in diabetes mellitus: an epidemiology and physiopathology review. Diabetol Metab Syndr 2016, 8, 63.
  6. Duff M., Demidova O., Blackburn S., Shubrook J.: Cutaneous manifestations of diabetes mellitus. Clin Diab 2015, 33, 40-48.
  7. Spravchikov N., Sizyakov G., Gartsbein M., Accili D., Tennenbaum T., Wertheimer E.: Glucose effects on skin keratinocytes: implications for diabetes skin complications. Diabetes 2001, 50, 1627-1635.
  8. Lima A.L., Illing T., Schliemann S., Elsner P.: Cutaneous manifestations of diabetes mellitus: a review. Am J Clin Dermatol 2017, 18, 541-553.
  9. Juranek J., Mukherjee K., Kordas B., Zalecki M., Korytko A., Zglejc-Waszak K., et al.: Role of RAGE in the pathogenesis of neurological disorders. Neurosci Bull 2022, 38, 1248-1262.
  10. Sorci G., Riuzzi F., Giambanco I., Donato R.: RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta 2013, 1833, 101-109.
  11. Yan S.F., Yan S.D., Ramasamy R., Schmidt A.M.: Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med 2009, 41, 408-422.
  12. Zglejc-Waszak K., Mukherjee K., Juranek J.K.: The cross-talk between RAGE and DIAPH1 in neurological complications of diabetes: a review. Eur J Neurosci 2021, 54, 5982-5999.
  13. Jaroslawska J., Korytko A., Zglejc-Waszak K., Antonowski T., Pomianowski A.S., Wasowicz K., et al.: Peripheral neuropathy presents similar symptoms and pathological changes in both high-fat diet and pharmacologically induced pre- and diabetic mouse models. Life (Basel) 2021, 11, 1267.
  14. Juranek J.K., Kothary P., Mehra A., Hays A., Brannagan 3rd T.H., Schmidt A.M.: Increased expression of the receptor for advanced glycation end-products in human peripheral neuropathies. Brain Behav 2013, 3, 701-709.
  15. Zglejc-Waszak K., Mukherjee K., Korytko A., Lewczuk B., Pomianowski A., Wojtkiewicz J., et al.: Novel insights into the nervous system affected by prolonged hyperglycemia. J Mol Med 2023, 101, 1015-1028.
  16. Zglejc-Waszak K., Schmidt A.M., Juranek J.K.: The receptor for advanced glycation end products and its ligands’ expression in OVE26 diabetic sciatic nerve during the development of length-dependent neuropathy. Neuropathology 2023, 43, 84-94.
  17. Abdi W., Romasco A., Alkurdi D., Santacruz E., Okinedo I., Zhang Y., et al.: An overview of S100 proteins and their functions in skin homeostasis, interface dermatitis conditions and other skin pathologies. Exp Dermatol 2024, 33, e15158.
  18. Yue Q., Song Y., Liu Z., Zhang L., Yang L., Li J.: Receptor for advanced glycation end products (RAGE): a pivotal hub in immune diseases. Molecules 2022, 27, 4922.
  19. Straino S., Di Carlo A., Mangoni A., De Mori R., Guerra L., Riccardo Maurelli R., et al.: High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J Investig Dermatol 2008, 128, 1545-1553.
  20. Lauria G., Lombardi R.: Skin biopsy: a new tool for diagnosing peripheral neuropathy. BMJ 2007, 334, 1159-1162.
  21. Juranek J.K., Geddis M.S., Rosario R., Schmidt A.M.: Impaired slow axonal transport in diabetic peripheral nerve is independent of RAGE. Eur J Neurosci 2013, 38, 3159-3168.
  22. Ramasamy R., Yan S.F., Schmidt A.M.: Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 2011, 1243, 88-102.
  23. Ramasamy R., Shekhtman A., Schmidt A.M.: The RAGE/DIAPH1 signaling axis and implications for the pathogenesis of diabetic complications. Int J Mol Sci 2022, 23, 4579.
  24. Radziszewski M., Galus R., Łuszczyński K., Winiarski S., Wąsowski D., Malejczyk J., et al.: The RAGE pathway in skin pathology development: a comprehensive review of its role and therapeutic potential. Int J Mol Sci 2024, 25: 13570.
  25. Park S.Y., Kim Y.A., Hong Y.H., Moon M.K.,Koo N.K., Kim T.W.: Up-regulation of the receptor for advanced glycation end products in the skin biopsy specimens of patients with severe diabetic neuropathy. J Clin Neurol 2014, 10, 334-341.
  26. Kanková K., Vasků A., Hájek D., Záhejský J., Vasků V.: Association of G82S polymorphism in the RAGE gene with skin complications in type 2 diabetes. Diabetes Care 1999, 22, 1745.
  27. Schleicher E.D., Wagner E., Nerlich A.G.: Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997, 99: 457-468.
  28. Miny S., Runel G., Chlasta J., Bonod C.: Influence of aging and diabetes on the mechanical properties of mouse skin. Dermatopathology 2025, 12, 18.
  29. Coll J.C., Turcotte A.F., Garceau É., Michou L., Weisnagel S.J., Mac-Way F., et al.: Skin and serum advanced glycation end products in adults with type 1 diabetes. Canad J Diabetes 2022, 46 Suppl 7, S25.
  30. Papachristou S., Pafili K., Papanas N.: Skin AGEs and diabetic neuropathy. BMC Endocrine Disord 2021, 21, 28.
  31. Salem S.A.M., El-Khateeb E.A., Harvy M., Emam H.M.E.S., Abdelaal W., El Nemr R., et al.: Study of serum levels and skin expression of S100B protein in psoriasis. An Brasil Dermatol 2017, 92, 323-328.
  32. Abdi W., Romasco A., Alkurdi D., Santacruz E., Okinedo I., Zhang Y., et al.: An overview of S100 proteins and their functions in skin homeostasis, interface dermatitis conditions and other skin pathologies. Exp Dermatol 2024, 33, e15158.
  33. Lallyett C., Yeung C.C., Nielson R.H., Zeef L.A.H., Chapman-Jones D., Kjaer M., et al.: Changes in S100 proteins identified in healthy skin following electrical stimulation: relevance for wound healing. Adv Skin Wound Care 2018, 31, 322-327.
  34. Wan R., Fang S., Zhang X., Zhou W., Bi X., Yuan L., et al.: S100A9 as a promising therapeutic target for diabetic foot ulcers. Chin Med J 2025, 138, 973-981.
  35. Abdulahad D., Westra J., Limburg P., Kallenberg C., Bijl M.: HMGB1 in systemic lupus erythematosus: its role in cutaneous lesions development. Autoimm Rev 2010, 9, 661-665.
  36. Karas A., Holmannova D., Borsky P., Fiala Z., Andrys C., Hamakova K., et al.: Significantly altered serum levels of NAD, AGE, RAGE, CRP, and elastin as potential biomarkers of psoriasis and aging – a case-control study. Biomedicines 2022, 10, 1133.
  37. Sun W., Xu J., Li S., Zhao Y., Fu J., Di L., et al.: GLUT1-mediated HMGB1 O-GlcNAcylation drives hyperglycemia-Induced neutrophil extracellular trap networks formation via TLR4 signaling and exacerbates fibroblast inflammation. Sci Rep 2025, 15, 1–12.
  38. Singh H., Agrawal D.K.: Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors. Drug Dev Res 2022, 83, 1257-1269
Copyright: © 2026 Polish Dermatological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Indeks osobowy
Share
without publication fees
without publication fees
Coverage in
Integrated with
plagiat pl
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications